经董事会批准，深圳高速公路集团股份有限公司（"本公司"）2020 年 4 月 14 日与有关各方签订了《晟创—深高速环科产业并购投资合伙企业（有限合伙） 之合伙协议》（"合伙协议"），共同投资设立晟创—深高速环科产业并购投资合伙 企业（有限合伙）（经工商登记机关核准为：佛山市顺德区晟创深高速环科产业 并购投资合伙企业（有限合伙），简称"环科产业并购基金"），基金总规模为人民 币 10 亿元，其中本公司认缴人民币 4.5 亿元，出资比例为 45%。根据合伙协议， 出资额分三次实缴，按 30%、30%和 40%的比例进行，环科产业并购基金自首期 实缴完成之日起 3 年为投资期，投资期届满后 3 年为回收退出期，经全体合伙人 同意可延长退出期，但最长不超过 2027 年 12 月 28 日。各合伙人已于 2020 年 6 月按照合伙协议的约定缴付首期出资，占认缴出资额的 30%，其中，本公司实缴 出资额为人民币 1.35 亿元。中国证券投资基金业协会已于 2020 年 8 月 27 日出 具环科产业并购基金的《私募投资基金备案证明》。其后，根据中国证券投资基 金业协会对环科产业并购基金备案所出具反馈意见的相关要求， ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其 準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容 而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 趙桂萍 公司秘書 中國，深圳，2025 年 10 月 10 日 （於中華人民共和國註冊成立的股份有限公司） （股份代號：00548） 海外監管公告 本公告乃根據香港聯合交易所有限公司證券上市規則第 13.10B 條而作出。 茲載列深圳高速公路集團股份有限公司（「本公司」）在上海證券交易所網站發布的《關 於環科產業併購基金進展的公告》，僅供參閱。 承董事會命 於本公告之日，本公司董事會的成員包括執行董事徐恩利先生、廖湘文先生、姚海先生 和文亮先生；非執行董事陳雲江先生、伍燕淩女士和張堅女士；以及獨立非執行董事李 飛龍先生、繆軍先生、徐華翔先生和顏延先生。 | 证券代码：600548 | 证券简称：深高速 | | | 公告编号：2025-087 | | --- | --- | --- | --- | --- | | 债券代码：188451 | 债券简称：21 | 深高 | 01 | | | 债券代码：185 ...

FF301 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年9月30日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 深圳高速公路集團股份有限公司 呈交日期: 2025年10月3日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 00548 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 747,500,000 | RMB | | | 1 RMB | | 747,500,000 | | 增加 / 減少 (-) | | | | | | | RMB | | | | 本月底結存 | | | 747,500,000 | RMB | | | 1 RMB | | 747,500,000 | | 2. 股份分類 ...

Major Events - Lai Kai Pharmaceutical-B (02105) reported positive preliminary results from Phase I clinical MAD study, with LAE102 showing encouraging trends in muscle gain and fat loss [1] - Fuhong Hanlin (02696) received FDA approval for the Phase I clinical trial application of HLX13 for first-line treatment of unresectable hepatocellular carcinoma (HCC) patients [1] - Ningmeng Media (09857) has commenced filming the urban medical emotional drama "Asking Heart 2" [1] - CRRC Corporation (01766) and its subsidiaries signed significant contracts totaling approximately 54.34 billion [1] - Heng Rui Pharmaceutical (01276) received approval to conduct clinical trials for SHR-7787 injection, SHR-4849 injection, Bevacizumab injection, and Atezolizumab injection [1] - Hema Medical (03309) entered into a tripartite global licensing and collaboration agreement with Gilead and Hanmi regarding enecuidar [1] - Jinfang Pharmaceutical-B (02595) completed the enrollment of the first patient in the Phase I/II clinical trial of the molecular glue Pan RAS(ON) inhibitor GFH276 for RAS mutant cancer patients [1] - Gao Shi Medical (02407) obtained international certification for its medical device quality management system [1] Operating Performance - Shenzhen Expressway Company (00548) reported toll revenue of 114 million for the Outer Ring project in August [1] - China National Automobile (00026) announced an annual performance with a post-tax loss attributable to shareholders of 185 million HKD, a year-on-year reduction of 29.64% [1] - OKURA HOLDINGS (01655) reported an annual profit attributable to shareholders of 1.342 billion JPY, a year-on-year decrease of 34.34% [1] - Elephant Future Group (02309) disclosed an annual performance with a loss attributable to owners of approximately 314 million HKD, a year-on-year increase of 71.77% [1] - Henghe Group (00513) reported an annual performance with a loss attributable to owners of approximately 259 million HKD, a year-on-year increase of 0.7% [1]

Core Points - The completion of the main span of the New Layer Bridge, part of the Changshen Expressway expansion project, marks a significant milestone for the project, laying a solid foundation for future operations [1][3] - The New Layer Bridge, a key control project, spans 190 meters and is designed as a prestressed concrete variable cross-section box girder structure, ensuring safety and efficiency during construction [1][3] Project Details - The bridge crosses the Jingjiu Railway at a 30-degree angle, with a clearance of over 11.96 meters from the bridge bottom to the track surface, meeting railway safety standards [1][3] - The Changshen Expressway expansion project, approximately 116.6 kilometers long, is a key project in Guangdong's 14th Five-Year Plan, enhancing connectivity between the Guangdong-Hong Kong-Macao Greater Bay Area and central regions like Jiangxi [3] - The project is currently in the final stages of construction, focusing on bridge deck, pavement, and ancillary works, aiming for full operation soon [3]

Core Insights - Bay Area Development (00737) announced toll revenue figures for August 2025, showing mixed performance across different highways [1] Toll Revenue Summary - The toll revenue for Guangshen Expressway (600548) in August 2025 was approximately 256 million, representing a year-on-year decrease of 0.5% [1] - The toll revenue for Guangzhu West Line Expressway was approximately 105 million, reflecting a year-on-year decrease of 12% [1] - The toll revenue for the Jiangjiang Expressway (Shenzhen section) was approximately 71.485 million, indicating a year-on-year increase of 1% [1] Traffic Impact Analysis - The changes in surrounding road networks in August 2025 had varying impacts on traffic volume, leading to different year-on-year revenue fluctuations for the three expressways [1]

Core Viewpoint - Shenzhen Expressway Company Limited (00548) received a notification from its major shareholder, China Merchants Highway Network Technology Holdings Co., Ltd. ("China Merchants Highway (001965)"), regarding the increase in shareholding in Shenzhen Expressway [1] Group 1: Shareholding Increase - China Merchants Highway increased its stake in Shenzhen Expressway by acquiring 25.374 million H-shares from April 16, 2025, to September 26, 2025, through centralized bidding [1] - As of September 26, 2025, China Merchants Highway directly holds 91,092,743 A-shares and 82,758,000 H-shares, totaling 6.85% of the company's total share capital [1] - Through its wholly-owned subsidiary, Cornerstone Holdings Limited, China Merchants Highway holds an additional 54,556,000 H-shares, representing 2.15% of the total share capital [1] - The combined shareholding of China Merchants Highway and Cornerstone Holdings amounts to 228,406,743 shares, which is 9.00% of the total share capital [1]

于2025年8月，广深高速公路、广珠西綫高速公路及沿江高速公路(深圳段)周边路网变化对车流量产生 不同影响，因此三条高速公路的路费收入按年变动幅度高低不一。 智通财经APP讯，湾区发展(00737)发布公告，于2025年8月，广深高速公路、广珠西线高速公路及沿江 高速公路(深圳段)月总路费收入分别约为2.56亿元、1.05亿元及7148.5万元，同比分别减少0.5%、减少 12%及增长1%。 ...

Core Viewpoint - Shenzhen Expressway Company Limited (00548) announced toll revenue projections for various projects in August 2025, indicating a positive outlook for revenue generation from these infrastructure assets [1] Revenue Summary - The projected toll revenue for the Meiguan Expressway is RMB 13.446 million [1] - The projected toll revenue for the Eastern Section of the Jihua Expressway is RMB 62.458 million [1] - The projected toll revenue for the Western Section of the Jihua Expressway is RMB 51.679 million [1] - The projected toll revenue for the Yangjiang Project is RMB 71.485 million [1] - The projected toll revenue for the Outer Ring Project is RMB 114 million [1]

截至 2025 年 9 月 26 日，招商公路直接持有公司 A 股 91,092,743 股，H 股 82,758,000 股，合计占公司 总股本的 6.85%;招商公路通过其全资子公司佳选控股有限公司(CORNERSTONE HOLDINGS LIMITED，"佳选控股")持有公司 H 股 54,556,000 股，占公司总股本的 2.15%;招商公路及佳选控股合计 持有公司股份 228,406,743 股，占公司总股本的 9.00%。 智通财经APP讯，深圳高速公路股份(00548)公布，公司于 2025 年 9 月 28 日收到公司持股 5%以上股东 招商局公路网络科技控股股份有限公司("招商公路")发来的《关于对深高速股票增持情况的告知函》， 告知招商公路于 2025 年 4 月 16 日至 2025 年 9 月 26 日期间通过集中竞价方式增持公司 H 股股票2537.4 万股。 ...